Melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Trump issued NSPM-7 (National Security Presidential Memorandum-7) on September 25, 2025, directing a government-wide strategy to counter what it characterizes as organized domestic terrorism and political violence. The memorandum cites "common threads" such as "anti-Americanism", "anti-capitalism", "anti-Christianity", support for 'overthrowing' the United States Government, and extremism related to migration, race, and gender. It assigns the National Joint Terrorism Task Force to lead investigations, directs the United States Department of Justice to prioritize prosecutions and consider domestic terrorist organization designations, and instructs the Department of the Treasury and the Internal Revenue Service to disrupt financial networks, while noting that the directive creates no enforceable rights. Thirty-one members of Congress later warned in a letter that NSPM-7 raises constitutional and civil-liberties concerns if used to target political dissent or ideological speech.
Hexapeptide-10 (SIKVAV, Serilesine) is a hexapeptide that is composed of a sequence Ser-Ile-Lys-Val-Ala-Val found at the C-terminus of the laminin α1 chain. Unlike other matrikine peptides which primarily act in the epidermis, hexapeptide-10 is active in deeper skin layers and promotes synthesis of laminin and integrin proteins, increases secretion of matrix metalloproteinases MMP2 and MMP9, and has angiogenic effects. Hexapeptide-10 promotes wound healing and tissue remodeling, and is used in skincare products with purported anti-aging effects. It has also been investigated for potential medical applications in the treatment of conditions such as Alzheimer's disease and muscular dystrophy. Due to its ability to promote angiogenesis, it can also promote tumour growth and is used in cancer research, though this requires concentrations many times higher than those used in skincare products.
However, in the middle of the night, Mundt releases Leamas and Nan from their cells and provides an escape plan for them both. Mundt explains that Leamas' real mission has succeeded; Mundt actually is a British agent, and Fiedler had been the target of the operation all along, as he had grown too suspicious of his supervisor. This comes as a shock to Leamas, and the complex web he has been drawn into and the risk he has been placed in by his own superiors become painfully clear. He explains the entire plot to still-idealistic Nan as they drive their borrowed car toward the border. She berates him for being involved in what amounts to the murder of Fiedler, who was only doing his job. Leamas, agitated by her naiveté, erupts in an angry, self-loathing confession:
==== History ==== All Sendai virus strains belong to the same serotype. The origin of many strains of SeV was described in 1978. Some strains such as Ohita and Hamamatsu were described later. Ohita and Hamanatsu strains were isolated from separate epidemics in laboratory mice. According to the personal memory of Alisa G. Bukrinskaya, who has co-authored numerous publications related to SeV along with Viktor M. Zhdanov, starting in 1961, the Moscow strain of SeV was obtained by Viktor M. Zhdanov of the Ivanovsky Institute of Virology from Japan in the late 1950s or early 1960s, It is reported that the BB1 strain derived from the Moscow virus strain. The strain BB1 was given to the researchers of Institute of Viral Disease Control and Prevention, Beijing, China by researchers of Ivanovsky Institute of Virology, Moscow, Russia in the 1960s.
Sources: en.wikipedia.org
=== Enhancement of physical performance === 1-MNA acts as a myokine, supporting the utilization of amino acids for gluconeogenesis in the liver and stimulating lipolysis in adipose tissue, thereby providing energy for muscles. Studies indicate that 1-MNA supplementation improves exercise tolerance and reduces fatigue. After one month of supplementation with 58 mg of 1-MNA, post-COVID-19 patients reported improved distances in a 6-minute walk test (6MWT), with 92% of participants experiencing better outcomes compared to controls. Additional studies highlight 1-MNA's ability to enhance physical performance by stimulating PGI2 release, protecting microcirculation, and ensuring adequate blood flow to muscle tissues. This mechanism may reduce cardiovascular risks associated with physical exertion, particularly in individuals with impaired endothelial response.
=== Tt theoretical model === Oftentimes, ELPs are not used in isolation, but are rather fused with other proteins to become functionally active. The structure of these other proteins will have a certain effect on transition temperature. It is important to be able to predict the transition temperature that these fusion proteins will have relative to the free ELPs, as this temperature will determine the fused protein's applicability and phase transition. A theoretical model is available that relates the change in Tt of the fused protein to the varying ratios of each individual amino acid found in the fused protein. The model involves calculating a surface index (SI) associated with each amino acid and then extrapolating, based on the ratio of each amino acid present in the fused protein, the total change in the Tt associated with the fusion protein, ΔTt,fusion: SI=
are fitting constants. Empirical correlations allow for extremely efficient estimates of physical properties, which can be useful in thermophysical simulations. However, they require high quality experimental data to obtain a good fit and cannot reliably extrapolate beyond the conditions covered by experiments.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.